StocksMedium•5 November 2026•
1 min read
Xeris Biopharma Revenue Surges 44% in Q3 as Company Raises Long-Term Guidance
Key Facts
1Xeris Biopharma reported a 44% year-over-year revenue increase to $107 million for the third quarter.
2The company raised its full-year 2026 and 2030 revenue outlooks.
Xeris Biopharma reported a 44% year-over-year revenue increase to $107 million for the third quarter of 2026. Benzinga reported that the company subsequently raised its revenue outlook for the full fiscal year 2026 and extended its positive guidance through 2030.
XERS closed at $10.46 on November 4, 2026, ahead of the results which highlight strong commercial performance. The stock traded between a low of $10.15 and a high of $10.71 on November 4, 2026.